Cargando…

Can Ciprofloxacin be Used for Precision Treatment of Gonorrhea in Public STD Clinics? Assessment of Ciprofloxacin Susceptibility and an Opportunity for Point-of-Care Testing

Background: Given the lack of new antimicrobials to treat Neisseria gonorrhoeae (NG) infections, reusing previously recommended antimicrobials has been proposed as a strategy to control the spread of multi-drug-resistant NG. We assessed ciprofloxacin susceptibility in a large sample set of NG isolat...

Descripción completa

Detalles Bibliográficos
Autores principales: Melendez, Johan H., Hsieh, Yu-Hsiang, Barnes, Mathilda, Hardick, Justin, Gilliams, Elizabeth A., Gaydos, Charlotte A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963864/
https://www.ncbi.nlm.nih.gov/pubmed/31615000
http://dx.doi.org/10.3390/pathogens8040189
_version_ 1783488379990573056
author Melendez, Johan H.
Hsieh, Yu-Hsiang
Barnes, Mathilda
Hardick, Justin
Gilliams, Elizabeth A.
Gaydos, Charlotte A.
author_facet Melendez, Johan H.
Hsieh, Yu-Hsiang
Barnes, Mathilda
Hardick, Justin
Gilliams, Elizabeth A.
Gaydos, Charlotte A.
author_sort Melendez, Johan H.
collection PubMed
description Background: Given the lack of new antimicrobials to treat Neisseria gonorrhoeae (NG) infections, reusing previously recommended antimicrobials has been proposed as a strategy to control the spread of multi-drug-resistant NG. We assessed ciprofloxacin susceptibility in a large sample set of NG isolates and identified correlates associated with ciprofloxacin-resistant NG infections. Methods: NG isolates collected in Baltimore, Maryland between 2014 and 2016 were evaluated by Gyrase A (gyrA) PCR and E-test for susceptibility to ciprofloxacin. Clinical characteristics and demographics were evaluated by multivariate regression analysis to identify correlates of ciprofloxacin-resistant NG infections. Results: 510 NG isolates from predominately African American (96.5%), heterosexual (85.7%), and HIV-negative (92.5%) male subjects were included in the study. The overall percentage of isolates with mutant gyrA sequences, indicative of ciprofloxacin resistance, was 32.4%, and significantly increased from 24.7% in 2014 to 45.2% in 2016 (p < 0.001). Participants older than 35 years of age were 2.35 times more likely to have a gyrA mutant NG infection than younger participants (p < 0.001). Race, sexual orientation, symptomology, or co-infection the HIV or syphilis were not associated with a particular NG gyrA genotype. Conclusions: Resistance to ciprofloxacin in Baltimore is lower than other regions and indicates that in this environment, use of ciprofloxacin may be appropriate for targeted treatment provided utilization of enhanced surveillance tools. The targeted use of ciprofloxacin may be more beneficial for individuals under 35 years of age. Point-of-care tests for NG diagnosis and susceptibility testing are urgently needed to identify individuals who can be treated with this targeted approach.
format Online
Article
Text
id pubmed-6963864
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-69638642020-01-27 Can Ciprofloxacin be Used for Precision Treatment of Gonorrhea in Public STD Clinics? Assessment of Ciprofloxacin Susceptibility and an Opportunity for Point-of-Care Testing Melendez, Johan H. Hsieh, Yu-Hsiang Barnes, Mathilda Hardick, Justin Gilliams, Elizabeth A. Gaydos, Charlotte A. Pathogens Article Background: Given the lack of new antimicrobials to treat Neisseria gonorrhoeae (NG) infections, reusing previously recommended antimicrobials has been proposed as a strategy to control the spread of multi-drug-resistant NG. We assessed ciprofloxacin susceptibility in a large sample set of NG isolates and identified correlates associated with ciprofloxacin-resistant NG infections. Methods: NG isolates collected in Baltimore, Maryland between 2014 and 2016 were evaluated by Gyrase A (gyrA) PCR and E-test for susceptibility to ciprofloxacin. Clinical characteristics and demographics were evaluated by multivariate regression analysis to identify correlates of ciprofloxacin-resistant NG infections. Results: 510 NG isolates from predominately African American (96.5%), heterosexual (85.7%), and HIV-negative (92.5%) male subjects were included in the study. The overall percentage of isolates with mutant gyrA sequences, indicative of ciprofloxacin resistance, was 32.4%, and significantly increased from 24.7% in 2014 to 45.2% in 2016 (p < 0.001). Participants older than 35 years of age were 2.35 times more likely to have a gyrA mutant NG infection than younger participants (p < 0.001). Race, sexual orientation, symptomology, or co-infection the HIV or syphilis were not associated with a particular NG gyrA genotype. Conclusions: Resistance to ciprofloxacin in Baltimore is lower than other regions and indicates that in this environment, use of ciprofloxacin may be appropriate for targeted treatment provided utilization of enhanced surveillance tools. The targeted use of ciprofloxacin may be more beneficial for individuals under 35 years of age. Point-of-care tests for NG diagnosis and susceptibility testing are urgently needed to identify individuals who can be treated with this targeted approach. MDPI 2019-10-14 /pmc/articles/PMC6963864/ /pubmed/31615000 http://dx.doi.org/10.3390/pathogens8040189 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Melendez, Johan H.
Hsieh, Yu-Hsiang
Barnes, Mathilda
Hardick, Justin
Gilliams, Elizabeth A.
Gaydos, Charlotte A.
Can Ciprofloxacin be Used for Precision Treatment of Gonorrhea in Public STD Clinics? Assessment of Ciprofloxacin Susceptibility and an Opportunity for Point-of-Care Testing
title Can Ciprofloxacin be Used for Precision Treatment of Gonorrhea in Public STD Clinics? Assessment of Ciprofloxacin Susceptibility and an Opportunity for Point-of-Care Testing
title_full Can Ciprofloxacin be Used for Precision Treatment of Gonorrhea in Public STD Clinics? Assessment of Ciprofloxacin Susceptibility and an Opportunity for Point-of-Care Testing
title_fullStr Can Ciprofloxacin be Used for Precision Treatment of Gonorrhea in Public STD Clinics? Assessment of Ciprofloxacin Susceptibility and an Opportunity for Point-of-Care Testing
title_full_unstemmed Can Ciprofloxacin be Used for Precision Treatment of Gonorrhea in Public STD Clinics? Assessment of Ciprofloxacin Susceptibility and an Opportunity for Point-of-Care Testing
title_short Can Ciprofloxacin be Used for Precision Treatment of Gonorrhea in Public STD Clinics? Assessment of Ciprofloxacin Susceptibility and an Opportunity for Point-of-Care Testing
title_sort can ciprofloxacin be used for precision treatment of gonorrhea in public std clinics? assessment of ciprofloxacin susceptibility and an opportunity for point-of-care testing
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963864/
https://www.ncbi.nlm.nih.gov/pubmed/31615000
http://dx.doi.org/10.3390/pathogens8040189
work_keys_str_mv AT melendezjohanh canciprofloxacinbeusedforprecisiontreatmentofgonorrheainpublicstdclinicsassessmentofciprofloxacinsusceptibilityandanopportunityforpointofcaretesting
AT hsiehyuhsiang canciprofloxacinbeusedforprecisiontreatmentofgonorrheainpublicstdclinicsassessmentofciprofloxacinsusceptibilityandanopportunityforpointofcaretesting
AT barnesmathilda canciprofloxacinbeusedforprecisiontreatmentofgonorrheainpublicstdclinicsassessmentofciprofloxacinsusceptibilityandanopportunityforpointofcaretesting
AT hardickjustin canciprofloxacinbeusedforprecisiontreatmentofgonorrheainpublicstdclinicsassessmentofciprofloxacinsusceptibilityandanopportunityforpointofcaretesting
AT gilliamselizabetha canciprofloxacinbeusedforprecisiontreatmentofgonorrheainpublicstdclinicsassessmentofciprofloxacinsusceptibilityandanopportunityforpointofcaretesting
AT gaydoscharlottea canciprofloxacinbeusedforprecisiontreatmentofgonorrheainpublicstdclinicsassessmentofciprofloxacinsusceptibilityandanopportunityforpointofcaretesting